Transmission of drug resistant HIV has been postulated to be a threat to current first line 22 antiretroviral therapy (ART) regimes and the efficacy of several antiretroviral based pre-23 exposure prophylaxis (PrEP) strategies being tested. Here we evaluated the effect of the common 24 tenofovir (TFV) resistance mutation, K65R on vaginal HIV transmission. Our results 25 demonstrate that despite no overt loss of overall replication competence in vivo, this mutation 26 results in significantly reduced mucosal transmission. When transmitted the mutant virus 27 eventually reverted to wild type in 2 of 3 animals examined. 28 TEXT 29
whereas all the mice exposed to the wild type virus were infected (4/4) only 25% of the mice 96 exposed to the mutant virus were infected (3/12). This difference in vaginal HIV transmission 97 was highly statistically significant by log rank analysis (p=0.011, Mantel Cox). These results 98 demonstrate that the K65R mutant is vaginally transmitted at a greatly reduced rate compared to 99 the wild type virus. Interestingly, these results seem at odds with those recently published by 100
Cong et al (11) using SIV. However, these could due to the facts that a different mutation was 101 used and that additional fitness compensatory mutations were introduced into the provirus used 102 
